CD14TLR4MD2

CD14TLR4MD2 is a heterotrimeric receptor complex composed of the surface glycoprotein CD14, the transmembrane protein Toll‑like receptor 4 (TLR4), and the soluble accessory protein MD‑2. It functions as a key pattern‑recognition receptor that detects lipopolysaccharide (LPS) from Gram‑negative bacteria. The complex is expressed predominantly on myeloid cells such as macrophages, monocytes, dendritic cells, and Kupffer cells, as well as on endothelial and certain epithelial cells. CD14 serves as a co‑receptor that transfers LPS to MD‑2, which directly binds the lipid A moiety of LPS. TLR4’s intracellular Toll/interleukin‑1 receptor (TIR) domain then recruits adaptor proteins MyD88 and TRIF, leading to activation of NF‑κB, MAPK, and IRF3 pathways that drive the transcription of pro‑inflammatory cytokines, chemokines, and type I interferons.

Structurally, MD‑2 is a secreted, cysteine‑rich protein that associates non‑covalently with the extracellular domain of TLR4, creating a canonical ligand‑binding pocket for LPS. CD14 is a GPI‑anchored glycoprotein that can exist in a soluble form in plasma; both forms enhance LPS sensitivity and facilitate the initiation of signal transduction. The ternary complex can also cooperate with co‑receptors such as CD16, CD36, and various integrins to modulate downstream signaling intensity.

Dysregulation of CD14TLR4MD2 signaling is implicated in sepsis, endotoxemia, atherosclerosis, metabolic syndromes, and certain autoimmune disorders. It is an attractive therapeutic target; antagonists that block LPS binding to MD‑2 or inhibitors that interfere with TLR4 dimerization have entered clinical development. Recent studies suggest that modulation of the complex by endogenous proteins, microRNAs, and post‑translational modifications can fine‑tune inflammatory responses. The CD14TLR4MD2 complex represents a cornerstone of innate immunity transcriptional networks and remains a focal point in research on host defense and inflammatory disease.